


Author's Accepted Manuscript

Engineering *Saccharomyces cerevisiae* for
production of simvastatin

Carly M. Bond, Yi Tang



www.elsevier.com/locate/ymben

PII: S1096-7176(18)30234-9
DOI: <https://doi.org/10.1016/j.ymben.2018.09.005>
Reference: YMBEN1466

To appear in: *Metabolic Engineering*

Received date: 7 June 2018
Revised date: 20 August 2018
Accepted date: 8 September 2018

Cite this article as: Carly M. Bond and Yi Tang, Engineering *Saccharomyces cerevisiae* for production of simvastatin, *Metabolic Engineering*, <https://doi.org/10.1016/j.ymben.2018.09.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Engineering *Saccharomyces cerevisiae* for production of simvastatin

Carly M. Bond^a, Yi Tang^{a,b}

^aDepartment of Chemical and Biomolecular Engineering, University of California, Los Angeles, California 90095, United States

^bDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States

Abstract

Simvastatin is a semisynthetic cholesterol-lowering medication and one of the top-selling statins in the world. Currently, industrial production of simvastatin acid (SVA) is a multistep process starting from the natural product lovastatin. For this reason, there is significant interest in direct production of simvastatin from a microbial host. In this study, six heterologous biosynthetic genes were introduced into *Saccharomyces cerevisiae* and the acyl-donor dimethylbutyryl-*S*-methyl mercaptopropionate (DMB-SMMP) was added, resulting in initial production of 0.5 mg/L SVA. Switching the yeast strain from JHY686 to BJ5464-NpgA increased total polyketide production to over 60 mg/L and conversion from dihydromonacolin L acid to monacolin J acid (MJA) was increased from 60 to 90% by tuning the copy number of the P₄₅₀ *lovA*. Increasing the media pH to 8.7 led to a further 10-fold increase in SVA production. Optimized chemical lysis of the cell walls *in situ* after maximum MJA production led to 55 mg/L SVA titer, representing nearly complete conversion from MJA and a 110-fold increase in titer from the initial SVA production strain. The yeast strains developed in this work can be used as an alternative production method for SVA, and the strategies employed can be broadly

Download English Version:

<https://daneshyari.com/en/article/11021612>

Download Persian Version:

<https://daneshyari.com/article/11021612>

[Daneshyari.com](https://daneshyari.com)